AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $356.11 billion. The enterprise value is $418.63 billion.
Important Dates
The next estimated earnings date is Friday, April 25, 2025, before market open.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | Apr 15, 2025 |
Share Statistics
AbbVie has 1.77 billion shares outstanding.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 73.21% |
| Float | 1.77B |
Valuation Ratios
The trailing PE ratio is 84.23 and the forward PE ratio is 16.40. AbbVie's PEG ratio is 1.37.
| PE Ratio | 84.23 |
| Forward PE | 16.40 |
| PS Ratio | 6.32 |
| Forward PS | 5.88 |
| PB Ratio | 106.89 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.97 |
| P/OCF Ratio | 18.94 |
| PEG Ratio | 1.37 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.67, with an EV/FCF ratio of 23.48.
| EV / Earnings | 98.78 |
| EV / Sales | 7.43 |
| EV / EBITDA | 15.67 |
| EV / EBIT | 22.84 |
| EV / FCF | 23.48 |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 20.22.
| Current Ratio | 0.66 |
| Quick Ratio | 0.43 |
| Debt / Equity | 20.22 |
| Debt / EBITDA | 2.51 |
| Debt / FCF | 3.81 |
| Interest Coverage | 6.53 |
Financial Efficiency
Return on equity (ROE) is 62.29% and return on invested capital (ROIC) is 16.13%.
| Return on Equity (ROE) | 62.29% |
| Return on Assets (ROA) | 8.49% |
| Return on Invested Capital (ROIC) | 16.13% |
| Return on Capital Employed (ROCE) | 19.01% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | $77,055 |
| Employee Count | 55,000 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 4.03 |
Taxes
| Income Tax | -570.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.81% in the last 52 weeks. The beta is 0.60, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +12.81% |
| 50-Day Moving Average | 195.43 |
| 200-Day Moving Average | 186.36 |
| Relative Strength Index (RSI) | 41.83 |
| Average Volume (20 Days) | 7,128,360 |
Short Selling Information
The latest short interest is 19.70 million, so 1.11% of the outstanding shares have been sold short.
| Short Interest | 19.70M |
| Short Previous Month | 19.62M |
| Short % of Shares Out | 1.11% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 3.10 |
Income Statement
In the last 12 months, AbbVie had revenue of $56.33 billion and earned $4.24 billion in profits. Earnings per share was $2.39.
| Revenue | 56.33B |
| Gross Profit | 39.65B |
| Operating Income | 18.33B |
| Pretax Income | n/a |
| Net Income | 4.24B |
| EBITDA | 26.72B |
| EBIT | 18.33B |
| Earnings Per Share (EPS) | $2.39 |
Full Income StatementBalance Sheet
The company has $5.56 billion in cash and $68.02 billion in debt, giving a net cash position of -$62.46 billion or -$35.31 per share.
| Cash & Cash Equivalents | 5.56B |
| Total Debt | 68.02B |
| Net Cash | -62.46B |
| Net Cash Per Share | -$35.31 |
| Equity (Book Value) | 3.36B |
| Book Value Per Share | 1.88 |
| Working Capital | -13.17B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $18.81 billion and capital expenditures -$974.00 million, giving a free cash flow of $17.83 billion.
| Operating Cash Flow | 18.81B |
| Capital Expenditures | -974.00M |
| Free Cash Flow | 17.83B |
| FCF Per Share | $10.08 |
Full Cash Flow StatementMargins
Gross margin is 70.37%, with operating and profit margins of 32.54% and 7.59%.
| Gross Margin | 70.37% |
| Operating Margin | 32.54% |
| Pretax Margin | 6.60% |
| Profit Margin | 7.59% |
| EBITDA Margin | 47.43% |
| EBIT Margin | 32.54% |
| FCF Margin | 31.65% |
Dividends & Yields
This stock pays an annual dividend of $6.56, which amounts to a dividend yield of 3.26%.
| Dividend Per Share | $6.56 |
| Dividend Yield | 3.26% |
| Dividend Growth (YoY) | 5.28% |
| Years of Dividend Growth | 53 |
| Payout Ratio | 274.48% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 3.20% |
| Earnings Yield | 1.19% |
| FCF Yield | 5.01% |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $212.70, which is 5.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $212.70 |
| Price Target Difference | 5.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 6.47% |
| EPS Growth Forecast (5Y) | 50.11% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.09 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 6 |